

**Cookies**

Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in [About Cookies](#).

I accept



Read a new COVID-19 **Rapid Review**.

**Cochrane Central Register of Controlled Trials****irritable bowel syndrome – improvement to the clinical situation by the use of humic acid**

ICTRP

<http://www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00005183>, 2013 | added to CENTRAL: 31 March 2019 | 2019 Issue 3

DRKS00005183

Links: [WHO ICTRP](#)

Abstract

INTERVENTION: Intervention 1: Verum (natural humic acid - Activomin®): intake of capsules orally (400mg per capsule) over 28 days (day 1-10: 3x2 capsules daily, day 11-28: 3x1 capsule daily) Intervention 2: placebo (rice flour colored with sepia): intake of capsules orally over 28 days (day 1-10: 3x2 capsules daily, day 11-28: 3x1 capsule daily)

CONDITION: K58 - Irritable bowel syndrome

PRIMARY OUTCOME: Change of IBS-Scores (Irritable Bowel Syndrome-Score, Francis 1997) and therefore the improvement of the subject state while having gastrointestinal dysfunctions on day 28 compared to day 0 (Baseline)

SECONDARY OUTCOME: Safety;; - adverse events ; - rescue medication according to patient diary; - number of patients with premature termination of the trial; efficacy: before and after comparison (day 0 and day 28) for; - Bristol Stool Form Scale ; - IBS-QOL for documentation of quality of life; - Quality of life (SF-36); - further explorative endpoints

INCLUSION CRITERIA: • irritable bowel syndrome - diarrhea-predominant (RDS-D) --> according to ROM III criteria (diarrhea / pain) • male and female patients = 18 years • patients, who are willing and able to realise the study visits (e.g. no planned holidays) • patients, who are willing and able to complete the patient diary • last to weeks (screening phase) at least two times complaints (pain, discomfort) per week • willing to forgo medications of the forbidden medication list • Written informed consent

Information

Database:

Cochrane Central Register of Controlled Trials (CENTRAL)

Date Added to CENTRAL:

31 March 2019

Issue Added to CENTRAL:

2019 Issue 3

Source:

<http://www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00005183>

Year of Publication:

2013

Original Title:

irritable bowel syndrome – improvement to the clinical situation by the use of humic acid - WH67® - irritable bowel syndrome

Accession Number:

ICTRP DRKS00005183

ID Number:

CN-01814812